臨床眼科74巻7号

2020年07月発行

連載 今月の話題

今までと異なる組み合わせの緑内障配合点眼薬をマスターしよう

著者： 齋藤代志明¹

所属機関： ¹さいとう眼科

ページ範囲：P.799 - P.806

文献概要

　アイベータ^®は，α₂作動薬であるブリモニジンとβ遮断薬であるチモロールを組み合わせた日本では今までになかった配合薬であり，房水産生抑制とぶどう膜強膜路流出促進の両方の作用を併せもつ。本稿では，アドヒアランスを考慮したアイベータ^®の使用位置づけについて，他の配合薬との比較および海外の報告から解説したい。

参考文献

1）日本緑内障学会：緑内障診療ガイドライン（第4版）．日眼会誌122：5-53，2018

2）Collaborative Normal-Tension Glaucoma Study Group：Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 126：487-497, 1998

3）Collaborative Normal-Tension Glaucoma Study Group：The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 126：498-504, 1998

4）Djafari F, Lesk MR, Harasymowycz PJ et al：Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma 18：238-243, 2009

5）Newman-Casey PA, Robin AL, Blachley T et al：The most common barriers to glaucoma medication adherence：A cross-sectional survey. Ophthalmology 122：1308-1316, 2015

6）Hahn SR：Patient-centered communication to assess and enhance patient adherence to glaucoma medication. Ophthalmology 116：S37-S42, 2009

7）Kashiwagi K, Furuya T：Persistence with topical glaucoma therapy among newly diagnosed Japanese patients. Jpn J Ophthalmol 58：68-74, 2014

8）Krupin T, Liebmann JM, Greenfield DS et al：A randomized trial of brimonidine versus timolol in preserving visual function：results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 151：671-681, 2011

9）Craven ER, Walters TR, Williams R et al：Brimonidine and timolol fixed-combination therapy versus monotherapy：a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 21：337-348, 2005

10）Motolko MA：Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2％ monotherapy versus fixed-combination brimonidine 0.2％-timolol 0.5％ therapy. Curr Med Res Opin 24：2663-2667, 2008

11）Hatanaka M, Grigera DE, Barbosa WL et al：An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5％/brimonidine tartrate 0.2％ versus fixed combination of timolol maleate 0.5％/dorzolamide 2％ in patients with elevated intraocular pressure. J Glaucoma 17：674-679, 2008

12）García-Feijoó J, Sáenz-Francés F, Martínez-de-la-Casa JM et al：Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol. Curr Med Res Opin 26：1599-1606, 2010

13）Nguyen QH, Earl M：Fixed-combination brimonidine/timolol as adjunctive therapy to a prostaglandin analog：a 3-month, open-label, replacement study in glaucoma patients. J Ocul Pharmacol Ther 25：541-544, 2009